IL6 and atrial fibrillation: The X-VeRT post hoc analyses have demonstrated that, in patients with AF undergoing planned cardioversion, anticoagulation with rivaroxaban is associated with a reduction in levels of key biomarkers of both coagulation (D-dimer and TAT) and inflammation (hs-IL-6 and hs-CRP).